Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorSteven A. Rosenberg
Estimating the term…
The present invention discloses a new approach to the therapy of cancer in humans based on the administration of lymphokine activated killer (LAK) cells and interleukin-2 (IL-2). Twelve patients with metastatic cancer who had failed standard available therapy were treated. LAK cells were generated from peripheral blood mononuclear cells obtained at multiple leukaphereses and incubated in the recombinant-derived lymphokine, IL-2. Following three to four days of incubation in IL-2, the resulting LAK cells were capable of lysing fresh tumor cells but not normal cells. These LAK cells were reinfused into the autologous patient, along with the intravenous administration of recombinant IL-2 every 8 hours. Patients received up to 90 doses of IL-2 and from 2.8 to 12.6.times.10.sup.10 activated cells from up to 14 sequential leukaphereses. Six patients showed objective regression of established cancer.
A method of treating cancer in humans comprising systemically administering to a human suffering from cancer other than sarcomas, an effective amount of interleukin-2 and interleukin-2-activated autologous human lymphocytes to cause regression of said cancer.
A method of treating cancer in humans comprising intraveneously administering to a human suffering from cancer other than sarcomas about 10.sup.6 to 10.sup.12 interleukin-2-activated human lymphocytes and about 10.sup.3 to 10.sup.6 units, per kilogram body weight, of interleukin-2 multiple times as tolerated by said human.
Dependencies are inferred from the claim text.